Differentiated strategy of domestic pharmaceutical companies to catch Atozet
In the ezetimibe market represented by ‘Vytorin’ and ‘Atozet,’ domestic pharmaceutical companies have gotten ready to enter.
The pharmaceutical companies have tried to attract interests of the market by differentiating the complex in combination of ‘Crestor(rosuvastatin),’ which has not been lau...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
